Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles by Maria S. Novak et al.
1 3
J Biol Inorg Chem (2016) 21:347–356
DOI 10.1007/s00775-016-1345-z
ORIGINAL PAPER
Biological properties of novel ruthenium‑ and osmium‑nitrosyl 
complexes with azole heterocycles
Maria S. Novak1 · Gabriel E. Büchel2 · Bernhard K. Keppler1 · Michael A. Jakupec1 
Received: 17 December 2015 / Accepted: 6 February 2016 / Published online: 9 March 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
accumulation of intracellular cyclic guanosine monophos-
phate attributable to NO-mediated effects was observed.
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Abbreviations
CCCP  Carbonyl cyanide 3-chlorophenylhydrazone
cGMP  Cyclic guanosine monophosphate
DCFH DA  Dichloro-dihydro-fluorescein diacetate
DMSO  Dimethyl sulfoxide
FITC  Fluorescein isothiocyanate
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid





NF-kB  Nuclear factor kappa-light-chain-enhancer of 
activated B cells
NO  Nitric oxide
PBS  Phosphate-buffered saline
PI  Propidium iodide
ROS  Reactive oxygen species
sGC  Soluble guanylate cyclase
Introduction
Efforts of many scientists around the world have been 
focused on the design of metal-based agents that can be 
successfully used in cancer therapy with a proper bal-
ance between activity and toxicity profiles, being active 
against cancer cells, but not too harmful to normal cells. 
Abstract Since the discovery that nitric oxide (NO) is 
a physiologically relevant molecule, there has been great 
interest in the use of metal nitrosyl compounds as antitumor 
pharmaceuticals. Particularly interesting are those com-
plexes which can deliver NO to biological targets. Ruthe-
nium- and osmium-based compounds offer lower toxicity 
compared to other metals and show different mechanisms 
of action as well as different spectra of activity compared 
to platinum-based drugs. Novel ruthenium- and osmium-
nitrosyl complexes with azole heterocycles were studied to 
elucidate their cytotoxicity and possible interactions with 
DNA. Apoptosis induction, changes of mitochondrial trans-
membrane potential and possible formation of reactive oxy-
gen species were investigated as indicators of NO-mediated 
damage by flow cytometry. Results suggest that ruthe-
nium- and osmium-nitrosyl complexes with the general 
formula (indazolium)[cis/trans-MCl4(NO)(1H-indazole)] 
have pronounced cytotoxic potency in cancer cell lines. 
Especially the more potent ruthenium complexes strongly 
induce apoptosis associated with depolarization of mito-
chondrial membranes, and elevated reactive oxygen species 
levels. Furthermore, a slight yet not unequivocal trend to 
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Ruthenium-based complexes show great promise, not only 
because of their lower toxicity compared to some other met-
als, but also because of different mechanisms of action and 
a different preference for protein rather than DNA binding 
in comparison to platinum drugs and a different spectrum 
of activity without pronounced cross-resistance [1, 2]. Over 
time, several ruthenium complexes were developed and 
studied for their antiproliferative activities against various 
cancer models, with the clinical development of NAMI-
A, KP1019 (Fig. 1) and NKP-1339 being the major mile-
stones in this field of research. NAMI-A shows little activity 
against primary tumors, but was found to be highly active 
against secondary tumors, particularly lung metastases, 
while the activity of KP1019 affects primary tumors as well, 
such as colorectal cancers which are resistant to cisplatin 
therapy [3–8]. Recently, NKP-1339 has been studied against 
solid tumors and showed promising results in a phase I clin-
ical trial, most remarkably in patients with gastrointestinal 
neuroendocrine tumors [9]. It was suggested that the tumor 
targeting properties of KP1019 and NKP-1339 are based on 
their reversible binding to serum proteins [10–12].
Nitric oxide releasing (pro)drugs of an organic (nitro-
glycerin) and inorganic (sodium nitroprusside) kind were 
already in clinical use for decades before the discovery 
that such a small molecule could act as a signaling mol-
ecule in biological systems [13–15]. In recent years, sev-
eral classes of exogenous NO donors have been synthe-
sized with the aim to investigate physiological processes 
controlled by different concentrations of nitric oxide in the 
cell. Some research groups studied the photochemistry of 
such compounds, and various strategies were developed to 
activate these compounds to release NO under the influ-
ence of visible or UV/IR light [16]. Generally, ruthenium 
nitrosyl complexes are attractive because of the thermal 
stability of the Ru–NO bond, which upon photochemical 
or electrochemical stimulation may release NO [17–21]. 
Besides this, it was proposed that the high affinity of NO to 
ruthenium might play a role in the mechanism of action of 
KP1019, which may act as an NO scavenger.
Nitric oxide is a highly reactive free radical containing 
an unpaired electron in its outermost orbital, allowing it to 
take part in many different reactions as an electron donor or 
Fig. 1  Structures of indazolium trans-tetrachloridobis(1H-indazole)ruthenate(III) (KP1019) and imidazolium trans-
tetrachlorido(dimethylsulfoxide)imidazoleruthenate(III) (NAMI-A)
Fig. 2  Nitric oxide is highly reactive molecule that is able to regulate 
a wide range of cell physiological processes
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acceptor and  is capable of enhancing various reactions and 
processes (Fig. 2). Thereby, NO is able to react with other 
inorganic molecules, DNA, prosthetic groups or with pro-
teins [22]. As a ligand in inorganic chemistry, NO is also 
known as a “non-innocent ligand”, implying that NO can 
adopt several oxidation states rendering the assignment of 
oxidation states for the ligand and the metal complicated. 
Furthermore, the geometry of NO bound to a metal can 
vary largely from being bound linearly to strongly bent, 
and being coordinated via N, O or both atoms at the same 
time. In biological systems, nitric oxide is an endogenous 
molecule that is produced by nitric oxide synthase (NOS) 
through the conversion of l-arginine to l-citrulline and NO 
[23]. Additionally, NOS-independent NO generation path-
ways starting from nitrate (NO3
−) and nitrite (NO2
−), pre-
viously thought to be inert, were discovered recently [24]. 
Activation of soluble guanylate cyclase (sGC), formation of 
cGMP, and concomitant protein phosphorylation is consid-
ered the main physiological signaling pathway of NO. This 
cGMP-dependent pathway activates various downstream 
targets including protein kinases, phosphodiesterases and 
ion channels; whereas cGMP-independent pathways can 
be related to S-nitrosylation, which leads to an inhibition 
of mitochondrial cytochrome oxidase. The physiological 
functions of NO include blood pressure control, neuro-
transmission, immunological responses, and antioxidant 
defense. All these effects are strongly dependent on the 
local NO bioavailability and concentration—while low 
concentrations of nitric oxide contribute to host defense, 
high concentrations may promote apoptosis [1, 20, 25]. The 
administration of NO donors reduces NF-kB activation and 
downstream expression of anti-apoptotic gene products, 
which is relevant for NO-dependent sensitization of chem-
otherapy-resistant tumor cells [26–28]. Mitochondrial dam-
age during NO-mediated apoptosis could be linked to the 
decrease of mitochondrial transmembrane potential due to 
the opening of mitochondrial permeability transition pores 
followed by massive ROS production [29].
To characterize in more detail the biological features of 
ruthenium- and osmium-nitrosyl complexes with the gen-
eral formula (indazolium)[cis/trans-MCl4(NO)(1H-inda-
zole)] (Fig. 3), we report here on cytotoxicity tests, flow 
cytometric detection of mitochondrial membrane depo-
larization, ROS generation and apoptotic cells, measure-
ment of intracellular cGMP levels as well as plasmid DNA 
interaction studies. Synthesis, physicochemical measure-
ments and stability in aqueous solutions as well as reactiv-
ity toward ascorbic acid, ubiquitin and myoglobin of these 
Fig. 3  Structures of ruthenium- 
and osmium-based nitrosyl 
complexes. Nitrogen atom 
labeling was introduced in 1c
350 J Biol Inorg Chem (2016) 21:347–356
1 3
complexes have been published previously [30]. It has also 
be shown by crystallographic structure determination that 
indazole binds only via N2 to the metal centers and not via 
N1 as recently found in particular for osmium compounds, 
an effect also influencing biological properties [31, 32]. 
X-ray crystallography also reveals that NO is bound line-
arly via the nitrogen atom, as already indicated by IR spec-
troscopic data as well as calculations [33]. Potentially bio-
logically relevant cis/trans isomerization reactions of these 
complexes were studied, revealing lower activation barriers 
for ruthenium than osmium compounds [34].
Materials and methods
Cell lines and culture conditions
CH1/PA-1 cells (identified via STR profiling as PA-1 ovar-
ian teratocarcinoma cells by Multiplexion, Heidelberg, 
Germany; compare Ref. [35]) were obtained from Lloyd 
R. Kelland, CRC Centre for Cancer Therapeutics, Institute 
of Cancer Research, Sutton, UK. SW480 (human adeno-
carcinoma of the colon), A549 (human non-small cell lung 
cancer) and HL-60 (human promyelocytic leukemia) cells 
were kindly provided by the Institute of Cancer Research, 
Department of Medicine I, Medical University of Vienna, 
Austria. All cell culture media and supplements were pur-
chased from Sigma-Aldrich, Austria and plastic ware 
from Starlab, Germany. Cells were grown in 75 cm2 cul-
ture flasks in complete medium (i.e., Minimum Essential 
Medium supplemented with 10 % heat-inactivated fetal 
bovine serum, 1 mM sodium pyruvate, 4 mM l-glutamine 
and 1 % non-essential amino acids from 100× ready-to-
use stock) as adherent monolayer cultures. Cultures were 
grown at 37 °C under a humidified atmosphere containing 
5 % CO2 and 95 % air.
MTT assay
Antiproliferative activity in vitro was determined by 
the colorimetric MTT assay (MTT = 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). For 
this purpose, cells were harvested from culture flasks by 
use of trypsin and seeded in complete medium (100 µL/
well) into 96-well plates in densities of 3 × 103 (A549), 
1 × 103 (CH1/PA-1) and 2 × 103 (SW480) cells per well. 
Cells were allowed for 24 h to settle and resume prolif-
eration. Test compounds were dissolved in DMSO first, 
appropriately diluted in complete medium and instantly 
added to the plates (100 µL/well), where the DMSO con-
tent did not exceed 0.5 %. After exposure for 96 h, the 
medium was removed and replaced with 100 μL/well of 
a 1:7 MTT/RPMI 1640 solution (MTT solution, 5 mg/mL 
of MTT reagent in phosphate-buffered saline; RPMI 1640 
medium, supplemented with 10 % heat-inactivated fetal 
bovine serum and 4 mM l-glutamine) and incubated for 4 h 
at 37 °C. Subsequently, the MTT/RPMI 1640 solution was 
removed, and the formazan product formed by viable cells 
was dissolved in DMSO (150 µL/well). Optical densities 
were measured with a microplate reader (BioTek ELx808) 
at 550 nm (and a reference wavelength of 690 nm) to 
yield relative quantities of viable cells as percentages of 
untreated controls, and 50 % inhibitory concentrations 
(IC50) were calculated by interpolation. Evaluation is based 
on at least three independent experiments with triplicates 
for each concentration level.
Neutral red uptake assay
Additionally, cell viability in vitro was investigated by the 
neutral red uptake assay (neutral red = 3-amino-7-dimeth-
ylamino-2-methylphenazine hydrochloride, Sigma). A549, 
CH1/PA-1 and SW480 cells were seeded in complete 
medium (100 µL/well) into 96-well plates in the same den-
sities as for MTT tests and were allowed for 24 h to settle 
and resume proliferation. Test compounds 1c and 1t were 
dissolved in DMSO first, appropriately diluted in complete 
medium and instantly added to the plates (100 µL/well), 
where the DMSO content did not exceed 0.5 %. After 
expose for 96 h, medium was replaced with 100 µL/well 
of a neutral red-containing medium. A neutral red stock 
solution (5 mg/mL) was prepared in phosphate-buffered 
saline, then diluted 1:100 in RPMI 1640 medium (sup-
plemented with 10 % heat-inactivated fetal bovine serum 
and 4 mM l-glutamine) and pre-incubated overnight at 
37 °C. Plates were incubated with this neutral red solu-
tion for 2 h at 37 °C to allow for the uptake into the lys-
osomes of viable cells. After incubation the medium was 
removed, cells were washed with phosphate-buffered saline 
two times (150 µL/well) and fixed with 1 % acetic acid in 
70 % ethanol (150 µL/well). After incubation for 10 min at 
RT, the absorption was measured with a microplate reader 
(BioTek ELx808) at 550 nm (and a reference wavelength 
of 690 nm) to yield relative quantities of viable cells as 
percentages of untreated controls, and 50 % inhibitory con-
centrations (IC50) were calculated by interpolation. Evalua-
tion is based on at least three independent experiments with 
triplicates for each concentration level.
Impact on mitochondrial membrane potential  
(JC‑1 assay)
Impairment of mitochondrial transmembrane potential was 
studied by flow cytometry using the lipophilic cationic dye 
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolyl-
carbocyanine iodide (JC-1). For this purpose, SW480 cells 
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were exposed to test compounds in different concentrations 
for 48 h at 37 °C and then collected in a density of 2 × 105 
cells/mL by centrifugation at 500g for 5 min. Afterwards, 
cells were washed with PBS and stained with 2 µg/mL 
JC-1 mix in complete medium for 15 min in the dark at 
37 °C. Then cells were washed and suspended in 500 µL of 
warm PBS and analyzed with a Guava 8HT EasyCyte flow 
cytometer (Millipore) using InCyte software. Carbonyl 
cyanide 3-chlorophenylhydrazone (CCCP) was used as a 
positive control in a concentration of 0.9 mM.
Flow cytometric detection of apoptotic cells
Induction of cell death was analyzed by flow cytometry 
using FITC-conjugated annexin V (BioVision, USA) and 
propidium iodide (PI, Fluka) double staining. SW480 cells 
were seeded into 12-well plates in a density of 5 × 104 
cells per well in complete medium and allowed to set-
tle for 24 h. The cells were exposed to test compounds in 
different concentrations for 48 h at 37 °C. The platinum 
complex KP1988 (synthesized at the Institute of Inorganic 
Chemistry, University of Vienna) was used as a positive 
control in a concentration of 200 μM. After incubation, 
cells were gently trypsinized, washed with PBS, and sus-
pended with FITC-conjugated annexin V (0.25 μg/mL) and 
PI (1 μg/mL) in binding buffer (10 mM HEPES/NaOH pH 
7.4, 140 mM NaCl, 2.5 mM CaCl2) at 37 °C for 15 min. 
Stained cells were analyzed with a Guava 8HT EasyCyte 
flow cytometer (Millipore) using InCyte software.
Detection of intracellular reactive oxygen species (ROS)
For the fluorimetric analysis of ROS, non-adherent HL60 
cells (promyelocytic leukemia, human) were stained for 
30 min at 37 °C under 5 % CO2 with 1 μM DCF-DA 
(2′,7′-dichlorofluorescein diacetate) in Hanks’ Balanced 
Salt Solution supplemented with 1% heat-inactivated fetal 
bovine serum. Cells were transferred into 96-well plates 
in a density of 6 × 104 cells/well and treated with the test 
substances at different concentrations for 30 min at 37 °C 
under 5 % CO2. A freshly prepared 500 μM H2O2 solu-
tion was used as a positive control and added 10 min before 
measurement. Cellular ROS levels were measured by flow 
cytometry on a Guava 8HT EasyCyte flow cytometer (Mill-
ipore). The resulting histograms of green fluorescence were 
quantified by FlowJo software (Tree Star). Results are pre-
sented as the ratios of green fluorescence intensities of the 
drug-treated samples and that of the untreated control.
Competition enzyme‑linked immunoassay (cGMP 
assay)
The intracellular cGMP levels after treatment with nitrosyl 
complexes were assessed by using the Cyclic GMP XP™ 
Assay Kit (Cell Signaling Technology). The teratocar-
cinoma cell line CH1/PA-1 was grown in 12-well plates 
under standard conditions and treated with various concen-
trations of test compounds for 2 h. Then, cells were solu-
bilized in lysis buffer, and intracellular cGMP levels were 
assessed according to manufacturer’s instructions. The 
absorbance was measured with a microplate reader (BioTek 
ELx808) at 450 nm, and the absolute amount of cGMP in 
samples was calculated by using a standard curve. Evalua-
tion is based on at least three independent experiments with 
duplicates for each concentration level.
Plasmid DNA interaction studies
pUC19 DNA (2686 bp) plasmid was purchased from Fer-
mentas Life Sciences. 500 ng of pUC19 plasmid was incu-
bated with 50 μM of the test compounds in 0.1× Tris-
EDTA (TE) buffer for different time intervals (5 min up to 
6 h) at 37 °C. The electrophoresis was performed in aga-
rose (from Sigma-Aldrich) gel 1 % w/v in 1× Tris-borate-
EDTA (TBE) buffer for 90 min at 80 V. Gels were stained 
with ethidium bromide (EtBr) in 1× TBE (0.75 μg/mL) for 
20 min. Images were taken with the multi-imaging detec-
tion system Fusion SL (Vilber Lourmat).
Results and discussion
As reported previously, ruthenium complexes 1c and 1t 
yielded IC50 values in the low micromolar range and turned 
out to be much more cytotoxic than osmium complexes 
2c and 2t (Table 1). Since the aqueous solubility of these 
Table 1  Inhibition of cancer 
cell growth by studied 
compounds in three human 
cancer cell lines; 50 % 
inhibitory concentrations 
(means ± standard deviations), 
obtained by the MTT assay 
and neutral red uptake assay 
(exposure time: 96 h)
a Taken from Ref. [30]
Compounds IC50, µM (MTT)a IC50, µM (neutral red)
A549 CH1/PA-1 SW480 A549 CH1/PA-1 SW480
1c 14 ± 3 2.7 ± 0.6 2.6 ± 0.3 20 ± 8 5.7 ± 2.5 4.3 ± 1.7
1t 8.0 ± 1.3 1.3 ± 0.3 1.1 ± 0.3 9.3 ± 2.9 2.3 ± 0.7 1.5 ± 0.4
2c 128 ± 18 48 ± 13 43 ± 6 n.d. n.d. n.d.
2t >640 145 ± 12 450 ± 35 n.d. n.d. n.d.
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complexes at 294 K is in the very low mM range, com-
pounds had to be dissolved in DMSO, but were diluted 
to acceptable DMSO contents to enable the application of 
up to very high submillimolar concentrations in biologi-
cal test. According to UV-vis spectroscopy (and ESI-MS) 
studies, complexes remain intact in aqueous solution for at 
least 24 h (Ru) and 72 h (Os), respectively. ESI-MS studies 
had also revealed that, in contrast to osmium analogs, the 
biologically much more active ruthenium compounds are 
prone to reduction by ubiquitous natural reducing agents 
such as ascorbic acid, suggesting that they can be activated 
by biological nucleophiles [30].
The strongest difference in cytotoxicity was observed 
between trans-configured ruthenium indazole complex 1t 
and its osmium analog 2t with a maximum factor of about 
400. The difference between the corresponding cis isomers 
1c and 2c was also pronounced with a maximum factor of 
18. In addition, the trans-configured ruthenium complex 1t 
is up to 2.4-fold more potent than its cis analog 1c, while 
the cis-configured osmium indazole complex 2c is up to 
tenfold more potent than its trans isomer 2t. For compari-
son, the antiproliferative activity of KP1019 tested previ-
ously yielded IC50 values of 44 ± 11 µM in CH1/PA-1 and 
79 ± 5 in SW480 cells [31]. Obviously, the exchange of 
one indazole present in KP1019 by NO increased the cyto-
toxic potency of ruthenium-based nitrosyl analog 1t about 
72 times in SW480 and about 34 times in CH1/PA-1 cells.
The first cytotoxicity tests had been performed using 
the MTT assay, which is based on the reduction of a tetra-
zolium salt to an insoluble formazan, reflecting the num-
ber of viable cells present. This reduction is catalyzed by 
mitochondrial enzymes as well as by cytoplasmic and cell 
membrane components [36]. Since nitric oxide can disrupt 
the mitochondrial respiratory system, the NO-mediated 
damage of mitochondria might distort the results of MTT-
based cytotoxic tests. Therefore, the activity of the most 
active compounds was confirmed by the neutral red uptake 
assay. This assay is based on the ability of viable cells to 
incorporate and bind the neutral red dye into lysosomes and 
likewise provides a quantitative estimation of the number 
of viable cells [37].
IC50 values obtained by the neutral red uptake assay are 
systematically slightly higher than those obtained by the 
MTT assay, with a maximum factor of 2.1 (for 1c in CH1/
PA-1 cells). However, these differences are too small to be 
taken as an indication for distortion of MTT-based cyto-
toxicity data by NO-mediated mitochondrial damage upon 
treatment with the tested substances.
The possible influence on mitochondria was addition-
ally investigated in SW480 cells by the lipophilic cationic 
dye JC-1. The JC-1 assay reveals depolarization of mito-
chondrial membranes in up to 55 and 68 % of cells after 
48 h exposure to ruthenium-based complexes 1c and 1t, 
respectively, and up to 20 and 4 % of cells for osmium-
based complexes 2c and 2t, respectively (Fig. 4). Thus, 
these experiments indicate a difference in the capacities of 
tested analogs to depolarize mitochondria: trans-configured 
ruthenium complex 1t induces mitochondrial membrane 
depolarization to an about 17 times higher extent than its 
osmium analog 2t, whereas cis-configured ruthenium com-
plex 1c does so only to an about 3 times higher extent than 
its osmium analog 2c.
Since the depolarization of mitochondrial membranes 
plays a role in the intrinsic apoptotic pathway, apoptosis 
induction was examined by annexin V-FITC/propidium 
iodide double staining in SW480 cells and subsequent flow 
cytometric analysis (Fig. 5). This assay is based on detec-
tion of phosphatidylserine externalization from the inner 
to the outer side of the plasma membrane upon apopto-
sis induction; the protein annexin V is able to bind to this 
externalized lipid, and the fluorescent tag FITC serves as 
a label for the flow cytometric detection of apoptotic cells. 
This is combined with propidium iodide, which indicates 
the loss of cell membrane integrity, differentiating necrotic 
and late apoptotic from early apoptotic and viable cells. 
These experiments indicate induction of apoptosis by 
ruthenium-based complexes 1c and 1t (50 µM) after 48 h 
in up to 80 and 83 % of cells, respectively, and by osmium-
based complexes 2c and 2t (250 µM) in up to 3 and 5 % 
of cells. Thus, the capacity of the cis-configured ruthenium 
indazole complex 1c to induce apoptosis is about 27 times 
higher than that of its osmium-based analog 2c. The trans-
configured ruthenium indazole complex 1t is about 17 
times more potent in this respect than its osmium analog 
2t. Together with the results of the JC-1 assay, this sug-
gests that only ruthenium, but not osmium-based nitrosyl 
complexes strongly induce programmed cell death via the 
intrinsic pathway involving depolarization of mitochondrial 
membranes.
Since the generation of oxidative stress is one of the 
known NO-mediated disturbances of the cell [39], we 
investigated by the DCF-DA assay the impact of nitrosyl 
complexes on the intracellular level of ROS in promyelo-
cytic leukemia cells HL60 (Fig. 6). The assay employs 
the cell-permeable fluorogenic probe DCF-DA, which is 
rapidly oxidized to highly fluorescent DCF by ROS and 
its fluorescence intensity is proportional to the ROS lev-
els within the cell. As an NO-free reference compound we 
used KP1019. The studies indicate a pronounced increase 
in ROS level by the trans-configured ruthenium indazole 
complex 1t only at the very high concentration of 250 µM 
(by a factor of 5.7), whereas the reference compound 
KP1019 consistently induces stronger increases (by up to 
13 times) and the other tested complexes only induce up to 
2.5-fold increases (at 250 µM). Thus, the trans-configured 
complex KP1019 lacking an NO ligand is about 2.3 times 
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more potently inducing ROS than the corresponding ruthe-
nium nitrosyl complex 1t and about 5 times more potent 
than the other complexes.
The possible involvement of the cGMP pathway, as 
a main NO-dependent signaling pathway in the cell, was 
examined by the competition enzyme-linked immunoas-
say in CH1/PA-1 cells (Fig. 7). Because of the competi-
tive nature of this assay, the magnitude of the absorbance 
is inversely proportional to the quantity of cGMP in the 
sample. Measurement of absorbance using a cGMP stand-
ard curve allows calculating the absolute amount of cGMP 
in a sample of interest. Obtained data suggest an up to 1.5-
fold increase in intracellular cGMP level upon treatment 
with trans-configured ruthenium indazole complex 1t at 
a concentration of 100 µM and a comparable effect of the 
cis-configured ruthenium indazole complex 1c at the high-
est concentration of 500 µM, but all effects are within the 
ranges of standard deviations and should therefore be taken 
with caution.
The interactions with plasmid DNA had been studied 
previously for KP1019, showing its ability to untwist and to 
bend DNA [10]. As analogs of KP1019, the nitrosyl com-
plexes were now studied for their ability to interact with 
DNA. Cell-free experiments showed no significant activity 
versus a dsDNA plasmid (Fig. S1). These experiments sug-
gest that ruthenium- and osmium-based nitrosyl complexes 
are unable to induce DNA damage under the experimental 
conditions.
In summary, the metal center variation and cis/trans 
isomerism in nitrosyl complexes bearing azole heterocy-
cles have an unexpectedly large impact on their potency 
in human cancer cell lines. Generally, ruthenium nitrosyl 
complexes showed a stronger capacity to inhibit cancer 
cell proliferation, to induce depolarization of mitochondrial 
membranes and apoptosis, and to increase intracellular 
ROS and cGMP levels than the osmium analogs. Overall, 
the cis-configured ruthenium nitrosyl complex is nearly as 
potent as the trans-configured complex except for ROS and 
cGMP assays.
The observed stronger activity of ruthenium complexes 
is remarkable and can be explained by differences in M–
NO bond stabilities. There is evidence that the Os–NO 
Fig. 4  Depolarization of mitochondrial membranes in SW480 cells after 48 h exposure to the tested compounds, measured by flow cytometry 
using JC-1 staining. Positive control was treated with 0.9 mM CCCP
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bond is stronger compared to the Ru–NO analog [40]. As a 
consequence, the ruthenium compounds are prone to reduc-
tion in the biological environment due to the decreased 
stabilization of the NO ligand compared to the Os coun-
terparts. Furthermore the ruthenium analogs can be acti-
vated by ascorbic acid, leading to hydrolysis of one chlo-
ride ligand in contrast to osmium analogs [30]. Ford has 
pointed out a “trans-effect” for ruthenium nitrosyls, which 
was more recently reviewed for octahedral transition metal 
complexes in general by Coe and Glenwright [18, 41]. Ford 
claims that the identity of the trans-ligand affects the M–
NO and N–O stretching frequencies; notably, X-ray struc-
tures of ruthenium nitrosyls showed that in the trans posi-
tion the M–ligand bond was significantly longer than in the 
cis-position. This is in line with previous research where 
it was shown that Ru−NO bonds in the cis isomer 1c are 
significantly shorter than in the trans isomer 1t because 
of the stronger trans effect of indazole compared to the 
Fig. 5  Apoptosis induction in SW480 cells after 48 h of exposure to the tested compounds, measured by flow cytometry using annexin V-FITC/
propidium iodide double staining. Positive control was treated with 200 µM of platinum(II) oxime complex KP1988 [38]
Fig. 6  Intracellular ROS levels in HL60 cells induced by tested com-
pounds, determined by the DCF-DA assay. RFUs of all samples were 
normalized to the RFU of stained untreated control (indicated by a 
dashed line)
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chlorido ligand [30]. This is also confirmed by thermody-
namic data showing a preference for the cis compound: 
cis to trans isomerization [−18.6 J/(mol K)] and [31.0 J/
(mol K)] for the trans to cis conversion. Kinetic data reveal 
the same picture with rate constants of 5.51 × 10−6 for the 
cis→trans process and 12.2 × 10−6 for the trans→cis pro-
cess at 100 °C in an aprotic solvent [34].
We come to the point that the understanding of the 
intracellular Ru–NO bond behavior is crucial for struc-
ture–activity relationships of this class of metallodrugs. If 
we take into account that the Ru–NO bond is more labile 
than the Os–NO bond, we may expect the release of NO 
under biological conditions as mentioned above. The role 
of NO in mitochondria-mediated cell death was reported 
several times before. Brown and co-workers describe a 
broad range of NO actions on mitochondria: it inhibits 
mitochondrial respiration, stimulates the production of 
superoxide, hydrogen peroxide and peroxynitrite, induces 
the transition permeability and release of cytochrome C, 
and NO potentially sensitizes cells to hypoxic damage 
[39]. Toledo et al. reported the ability of ruthenium(II) 
ammine nitrosyl complexes to release NO under biological 
conditions, where the reduction of these complexes is con-
comitant with mitochondrial NADH oxidation [42]. Curti 
and co-authors also observed NO release for this com-
pound class which was occurring as a result of NAD(P)
H oxidation and led to dissipation of mitochondrial mem-
brane potential, ATP depletion and generation of ROS. 
As described in the most recent publication, oxidation of 
mitochondrial NADH promotes NO release from nitrosyl 
ruthenium complexes, which is accompanied by the 
release of cytochrome C [43, 44].
Thus far, our results demonstrate that the studied ruthe-
nium nitrosyl complexes induce apoptosis by the mitochon-
drial pathway, at least partially associated with ROS gen-
eration, and may represent promising drug candidates for 
further preclinical evaluation.
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